Despite the successes and limitations of these de-escalation strategies, most patients with early-stage, HER2-positive breast cancer are still treated with chemotherapy today; therefore, there is a need for implementing new tools to help guide the use of cytotoxic therapy in early-stage, HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.